clinical trials

The European Commission has approved Roche’s Gazyvaro (obinutuzumab) for previously untreated patients with advanced follicular lymphoma. The treatment is approved in combination with chemotherapy and should be followed by Gazyvaro maintenance ... Read more

Lymphoma patients’ response to Sandoz’s biosimilar therapy GP2013 was similar to their response to the treatment from which it is derived, Genentech’s Rituxan (rituximab), a Phase 3 clinical trial indicates. Sandoz ... Read more

Two Phase 3 trials will assess the potential of Bayer’s copanlisib in combination with other treatment in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma, based on positive data from ... Read more

The U.S. Food and Drug Administration (FDA) has approved Bayer’s Aliqopa (copanlisib) for patients with follicular lymphoma who have relapsed after at least two earlier therapies. The agency granted Aliqopa an ... Read more

Verastem’s duvelisib was seen to outperform Arzerra (ofatumumab) in a Phase 3 trial of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the company ... Read more

The U.S. Food and Drug Administration has approved Pfizer’s Mylotarg (gemtuzumab ozogamicin) for adults and children with acute myeloid leukemia (AML) whose cancer carries the CD33 marker. In adults, ... Read more

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental biologics license application (sBLA) seeking the approval of Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone, for patients with previously ... Read more

The first participant has begun treatment in a new Phase 3 clinical trial assessing Astellas Pharma‘s gilteritinib as a maintenance therapy for certain acute myeloid leukemia (AML) patients who are in ... Read more

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) required to bring Seattle Genetics’ Adcetris (brentuximab vedotin) to the market for the ... Read more

Disclaimer:

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.